Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174041 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT03174041 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 63 participants.
The verdict
NCT03174041, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the potential for a drug interaction between GDC-0853 and midazolam, itraconazole, rosuvastatin, and simvastatin.
Interventions
- DRUG Midazolam
- DRUG Rosuvastatin
- DRUG GDC-0853
- DRUG Midazolam and GDC-0853
- DRUG Rosuvastatin and GDC-0853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2017-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03174041
The ClinicalTrials.gov registry entry for NCT03174041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT03174041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03174041 about?
NCT03174041 is a clinical study titled "A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin". The purpose of this study is to assess the potential for a drug interaction between GDC-0853 and midazolam, itraconazole, rosuvastatin, and simvastatin.
What is the current status of trial NCT03174041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2017-04-18. Estimated completion is 2017-06-23.
What interventions are being tested in trial NCT03174041?
The interventions under investigation include: Midazolam (DRUG), Rosuvastatin (DRUG), GDC-0853 (DRUG), Midazolam and GDC-0853 (DRUG), Rosuvastatin and GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT03174041?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.